2500 — Venus MedTech HangZhou Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro Cap

Annual income statement for Venus MedTech HangZhou, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	233	276	416	406	491
Cost of Revenue
Gross Profit	195	227	324	314	389
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	593	458	780	1,504	1,169
Operating Profit	-360	-182	-364	-1,098	-677
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-382	-186	-378	-1,156	-752
Provision for Income Taxes
Net Income After Taxes	-381	-183	-371	-1,122	-746
Minority Interest
Net Income Before Extraordinary Items
Net Income	-381	-182	-374	-1,058	-721
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-381	-182	-374	-1,058	-721
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-1.17	-0.444	-0.497	-1.76	-1.28